Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
PHASE3CompletedINTERVENTIONAL
Enrollment
622
Participants
Timeline
Start Date
October 13, 2015
Primary Completion Date
April 11, 2019
Study Completion Date
November 10, 2020
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
BIOLOGICAL
pembrolizumab
DRUG
capecitabine
DRUG
eribulin
DRUG
gemcitabine
DRUG
vinorelbine
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02555657 - Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) | Biotech Hunter | Biotech Hunter